HS-20105 binds TROP-2 on tumor cells, is internalized, and releases a topoisomerase I inhibitor that blocks DNA replication and triggers apoptosis in TROP-2–positive cells; DNA topoisomerase I is the payload’s enzyme target, not the antigen selected by the drug.